Diese Seite ist nur für medizinisches Fachpersonal in Deutschland

sitemap-desktop.png site-map-mobile.

SITEMAP

  • 1. Opzelura® Fachinformation. Aktueller Stand.
  • 2. Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021;48(3):252–270.
  • 3. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatol Basel Switz. 2020;236(6):571–592.
  • 4. Chen X, Guo W, Chang Y, et al. Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo. Free Radic Biol Med. 2019;139:80–91.
  • 5. Richard MA, Paul C, Nijsten T, et al. Prevalence of most common skin diseases in Europe: a population based study. J Eur Acad Dermatol Venereol JEADV. 2022;36(7):1088–1096.
  • 6. Mohr N, Petersen J, Kirsten N, et al. Epidemiology of Vitiligo - A Dual Population-Based Approach. Clin Epidemiol. 2021;13:373–382.
  • 7. Boniface K, Seneschal J, Picardo M, et al. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clin Rev Allergy Immunol. 2018;54(1):52–67.
  • 8. Silverberg JI, Silverberg NB. Vitiligo disease triggers: psychological stressors preceding the onset of disease. Cutis. 2015;95(5):255–262.
  • 9. Hadi A, Wang JF, Uppal P, et al. Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. J Am Acad Dermatol. 2020;82(3):628–633.
  • 10. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2016;74(2):295–302.
  • 11. Korde S, Gugle A, Pawar M. A study of association of diabetes mellitus and vitiligo patients. MVP J Med Sci. 2018;5(2):125–133.
  • 12. Picardo M, Dell’Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primer. 2015;1:15011.
  • 13. Krüger C, Schallreuter KU. Stigmatisation, Avoidance Behaviour and Difficulties in Coping are Common Among Adult Patients with Vitiligo. Acta Derm Venereol. 2015;95(5):553–558.
  • 14. Bibeau K, Hamzavi I, Ezzedine K. Mental health and psychosocial burden among patients living with vitiligo: findings from the global VALIANT study. Presented at Maui Derm for Dermatologists. 2022.
  • 15. Zhang H, Yang Z, Tang K, et al. Stigmatization in Patients With Psoriasis: A Mini Review. Front Immunol. 2021;12:715839.
  • 16. Phan K, Shumack S, Gupta M. Association between vitiligo and risk of suicide and suicidal ideation: systematic review and meta-analysis. Pigment Int. 2022;9(2):127.
  • 17. Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 202;22(6):757–774.
  • 18. van Geel N, Moock C, Zuidgeest M, et al. Patients’ Perception of Vitiligo Severity. Acta Derm Venereol. 2021;101(6):adv00481.
  • 19. Radtke MA, Schäfer I, Gajur A, et al. Willingness-topay and quality of life in patients with vitiligo. Br J Dermatol. 2009;161(1):134–139.
  • 20. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159–164.
  • 21. Bibeau K, Parsad D, Harris J. Exploring the natural and treatment history of vitiligo: findings from theglobal VALIANT study. Presented at Maui Derm forDermatologists. 2022.
  • 22. Abdel-Malek ZA, Jordan C, Ho T, et al. The enigma andchallenges of vitiligo pathophysiology and treatment.Pigment Cell Melanoma Res. 2020;33(6):778–787.
  • 23. Eleftheriadou V, Thomas KS, Whitton ME, et al. Which out comes should we measure in vitiligo? Results of asystematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol.2012;167(4):804–814.
  • 24. Taieb A. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br AssocDermatol. 2012;(168):5–19.
  • 25. FDA. The Voice of the Patient: A series of report from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative [Internet]. 2021. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda. gov/media/155068/download (Accessed February 2023).
  • 26. Bibeau K, Harris J, LaFiura C. Diagnosis and management of vitiligo from the perspectives of patients and healthcare professionals: findings from the global VALIANT study. Presented at: Maui Derm for Dermatologists.
  • 27. Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol. 2016;43:81–88.
  • 28. Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013;25(6):676–682.
  • 29. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020;38:621–648.
  • 30. Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol. 2019;10:2342.
  • 31. Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017;35(2): 257–265.
  • 32. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, Phase 2 trial. Lancet Lond Engl. 2020;396(10244):110–120.
  • 33. Nolz JC, Richer MJ. Control of memory CD8+ T cell longevity and effector functions by IL-15. Mol Immunol. 2020;117:180–188.
  • 34. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445–1455.
  • 35. Birlea SA, Goldstein NB, Norris DA. Repigmentation through Melanocyte Regeneration in Vitiligo. Dermatol Clin. 2017;35(2):205–218.
  • 36. Passeron T. Medical and Maintenance Treatments for Vitiligo. Dermatol Clin. 2017;35(2):163–170.
  • 37. Incyte Biosciences International Sarl. Data on File.
  • 38. Gan EY, Eleftheriadou V, Esmat S, et al. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2017;30(1):28–40.
  • 39. Lei TC, Hearing VJ. Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved. Chin Med J (Engl). 2020;133(10):1231–1238.
  • 40. Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677–683.
  • 41. Bae JM, Zubair R, Ju HJ, et al. Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index. J Am Acad Dermatol. 2022;86(2):387–393.
  • 42. Batchelor JM, Tan W, Tour S, et al. Validation of the Vitiligo Noticeability Scale: a patient reported outcome measure of vitiligo treatment success. Br J Dermatol. 2016;174(2):386–394.
  • 43. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–3117.
  • 44. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, et al. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021;22(2):797.
  • 45. Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18–29. 46. Bagherani N. Role of corticosteroids in treatment of vitiligo. In: Magdeldin S, editor. State Art Ther Endocrinol. 2012. 47. Ko HC, Kim WI, Cho SH, et al. Topical Tacrolimus for the Treatment of Atopic Dermatitis with Truncal Lesion.Ann Dermatol. 2018;30(2):173–178.
  • 46. Bagherani N. Role of corticosteroids in treatment of vitiligo. In: Magdeldin S, editor. State Art Ther Endocrinol. 2012.
  • 47. Ko HC, Kim WI, Cho SH, et al. Topical Tacrolimus for the Treatment of Atopic Dermatitis with Truncal Lesion.Ann Dermatol. 2018;30(2):173–178.